Enliven Therapeutics, Inc. · NASDAQ:ELVN

Collins Helen Louise sold 5,000 Enliven Therapeutics, Inc. shares (Form 4)

Traded Jun 17, 2026 · Filed Jun 22, 2026

On Jun 17, 2026, Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 Enliven Therapeutics, Inc. shares at an average US$43.80 for US$219K under a trading plan, leaving 25,000 shares. Filed Jun 22, 2026 (Form 4).

Sold
5,000 shares
Price
US$43.80 average (US$42.83 to US$44.74)
Value
US$219K
Holding after
25,000 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF MEDICAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 17, 2026Common StockOption exercise5,000US$2.4830,000Direct
Jun 17, 2026Common StockSale1,268US$42.8328,732Direct
Jun 17, 2026Common StockSale2,599US$43.8726,133Direct
Jun 17, 2026Common StockSale1,133US$44.7425,000Direct

Source

View original at SEC

Related